Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer — Hypo-M1  

Prostate Cancer Clinical Trial

Official title: A Randomized Phase III, Multicenter Study to Evaluate Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer

Status Recruiting

Clinical Trial Summary

de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.

Clinical Trial Description

Patients with de Novo metastatic prostate cancer with limited disease spread has been shown to gain benefit from local radiotherapy to the prostate. The internationally accepted fractionation schedule is 3 Gy (Gray) x 19-20 over a course of 4 weeks.

There is continous evidence for even more hypo-fractionated radiotherapy with higher fractionation doses. We will test if the schedule of 6.1Gy x 6 compares to standard of 3 Gy x 19 with regard to patient reported side-effects. ;

Related Conditions & MeSH terms

• Metastatic Cancer
• Prostate Cancer
• Prostatic Neoplasms
• Radiotherapy Side Effect

• NCT number: NCT04612907
• Study type: Interventional
• Source: Umeå University
• Contact: Camilla Thellenberg Karlsson, MD, PhD
• Phone: +46 90 785 3296
• Email: camilla.thellenberg@umu.se
• Status: Recruiting
• Phase: N/A
• Start date: October 31, 2022
• Completion date: September 30, 2032